Periodontal Therapy by Local Delivery of Minocycline: Clinical Study of Periodontal Therapy by LS-007

Our previous studies have been performed to establish methods for local delivery of Minocycline hydrochloride (MINO: Lederle Japan, LTD, Tokyo) in a therapy for periodontal disease. This study was done clinically to evaluate the effectiveness, safety, and usefulness of a LS-007 medicine containing 2 percent titers of MINO. Forty five periodontitis patients (119 teeth) with periodontal pockets (≥4mm) participated in this study. The experimental systems were evaluated by comparing microbiological and clinical effectiveness of LS-007, placebo, and Minocycline tablet (Lederle Japan, LTD). The results were as follows, 1. The effectiveness of LS-007 was examined in two delivery system ; in one system the medicine was redelivered after one week, and in the other system after two weeks. Both systems revealed similar effectiveness until after two weeks from the last delivery. 2. When LS-007 was delivered once in a week for 4 successive weeks, LS-007 demonstrated its effectiveness until after 4 weeks from the last delivery. 3. A pretreatment with scaling prior to the application of LS-007 raised the effectiveness of LS-007. 4. The systemic delivery of Minomycine tablet demonstrated microbiologically and clinically similar effect to the local delivery of LS-007. In the systemic delivery, however, there was a subject who suffered harmful side effect of the medicine. From these results, we concluded the local delivery of LS-007 was clinically effective, safe, and useful as a therapy for periodontal disease.